InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InflaRx N.V. (Nasdaq: IFRX) announced the completion of its public offering of 9,411,765 ordinary shares, raising approximately $46 million after the underwriters exercised their option to purchase an additional 1,411,764 shares at a price of $4.25 each. The proceeds will fund the development of vilobelimab, research and development expenses, and investments in commercial infrastructure. Raymond James & Associates served as the sole book-running manager for this offering, and a shelf registration statement was declared effective by the SEC on July 17, 2020. The offering's details, including the prospectus, are available through the SEC's website or directly via Raymond James.
InflaRx N.V. (Nasdaq: IFRX) has completed an underwritten public offering of 9,411,765 ordinary shares at a price of $4.25 per share, raising approximately $40 million in gross proceeds. The underwriters were granted a 30-day option to purchase an additional 1,411,764 shares. The funds will be allocated towards the ongoing development of vilobelimab, general research and development, and strengthening the company’s commercial infrastructure. The offering was facilitated through a shelf registration statement effective since July 17, 2020, with all necessary filing made with the SEC. InflaRx is focused on developing innovative therapies targeting the complement system, particularly in addressing autoimmune and inflammatory diseases.
InflaRx N.V. (Nasdaq: IFRX) announced a public offering of 9,411,765 ordinary shares at a price of $4.25 per share, expected to close on April 14, 2023. An additional 1,411,764 shares are available for purchase by underwriters. The net proceeds will support the development of vilobelimab, general R&D expenses, and corporate needs. The offering is made under a shelf registration statement declared effective by the SEC on July 17, 2020. Raymond James & Associates is the sole book-running manager, with LifeSci Capital as co-manager. This press release serves as a notice and does not constitute an offer or solicitation to sell securities.